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Laparoscopic versus Open Radical Nephrectomy in T2 Renal Cell 
Carcinoma: Long-Term Oncologic Outcomes
Se Yun Kwon, Jae Wook Jung, Bum Soo Kim, Tae-Hwan Kim, Eun Sang Yoo, Tae Gyun Kwon 
Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea
Purpose: Laparoscopic radical nephrectomy (LRN) has become the standard technique 
for radical nephrectomies for T1 renal tumors (7 cm or less). We extended our experience 
with LRN to T2 renal tumors (greater than 7 cm) and compared the efficacy and 
long-term oncologic outcomes with those of open radical nephrectomy (ORN) for T2 
clear renal cell carcinoma (RCC) in the same period. 
Materials and Methods: We retrospectively analyzed the data from 33 patients who 
underwent LRN and 35 patients who underwent ORN in our institution from January 
2003 to June 2006 for T2N0M0 RCC. We compared long-term oncologic outcomes be-
tween the two groups. 
Results: The median follow-up periods were 60.0 months (range, 48.0-77.0 months) and 
65.6 months (range, 56.0-77.0 months) in the LRN and ORN groups, respectively. There 
were no statistically significant differences between the two groups in the patients’
demographic data. There were no significant differences in the 5-year overall survival 
rate, the cancer-specific survival rate, or the recurrence-free survival rate. 
Conclusions: Our results suggest that LRN for the management of T2 RCC is feasible 
and efficacious and that the long-term oncologic outcomes of LRN are comparable to 
those of ORN.
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INTRODUCTION
Since the first series of laparoscopic nephrectomies were 
introduced in 1991 by Clayman et al [1], laparoscopic radi-
cal nephrectomy (LRN) has become the standard techni-
que for radical nephrectomies for T1 renal tumors (7 cm or 
less), except in favorable cases of nephron-sparing surgery 
[2,3]. Multiple studies have repeatedly shown the feasi-
bility, the low morbidity, and the excellent oncologic effi-
cacy of LRN [2-9]. However, most of the current literature 
has focused on LRN for masses that are less than 7 cm, 
which are now more often treated with nephron-sparing 
surgery. Although the indications for LRN are being ex-
panded to include masses larger than previously indicated, 
the literature to date lacks studies addressing the 
long-term outcomes of laparoscopic nephrectomy for mass-
es greater than 7 cm, although several recent publications 
have reported on surgical outcomes [10-13]. Moreover, 
there are currently no reports on the long-term oncologic 
outcomes of LRN for T2 renal tumors in Korea.
We retrospectively evaluated patients undergoing LRN 
for large tumors (greater than 7 cm) at our center and com-
pared their long-term oncologic outcomes with those from 
a similar cohort of patients undergoing open radical neph-
rectomy (ORN) during the same period.  
MATERIALS AND METHODS
From January 2003 to June 2006, 68 patients underwent 
radical nephrectomy for T2 renal cell carcinoma (RCC) (33 
LRN and 35 ORN). The choice of surgical procedure was 
based on referrals and surgeon preference. All cases were 
pathologically confirmed as clear cell carcinoma. Patients 
with T3-stage, T4-stage, or metastatic disease were exclud-Korean J Urol 2011;52:474-478
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TABLE 1. Comparison of patients’ demographic data and perioperative surgical outcomes between LRN and ORN
LRN ORN p-value
No. of patients
Age (yr)
Sex (M/F)
BMI (kg/m
2)
Tumor laterality (Rt/Lt)
Mean tumor size (cm)
Tumor grade (Fuhrman)
2
3
4
Operation time (min)
ABL (ml)
Transfusion rate (%)
Complication rate (%)
33
  56.1±11.9
24/9
24.4±2.6
  21/12
  8.2±1.2
14
18
  1
209.0±55.3
  287.6±281.1
  7/33 (21.2)
2/33 (6.0)
35
  55.0±10.8
  22/13
23.2±3.1
  16/19
  9.0±2.0
15
18
  2
205.1±48.5
  431.5±269.6
  6/35 (17.1)
  5/35 (14.2)
0.700
0.385
0.104
0.138
0.593
0.857
0.755
0.035
0.314
0.265
BMI: body mass index, ABL: actual blood loss (EBVx(Hgbi−Hgbf) / ((Hgbi＋Hgbf)/2)＋(500xT(u)), Hgbi: preoperative hemoglobin, Hgbf:
postoperative day one morning hemoglobin, T(u): sum of autologous whole blood (AWB), packed red blood cells (PRBC), and cell saver
(CS) units, LRN: laparoscopic radical nephrectomy, ORN: open radical nephrectomy. Data presented as the mean±standard deviation
ed. Study participants were followed up for at least 48 
months. 
The demographic parameters included age, body mass 
index (BMI), gender, and tumor laterality. The pathologic 
data included tumor size and grade (Fuhrman’s nuclear 
grading system). To evaluate operative outcomes, we com-
pared operative time, actual blood loss (ABL) [14], the 
transfusion rate, and the complication rate. To analyze the 
oncologic outcomes, we compared 5-year overall survival, 
recurrence-free survival, and cancer-specific survival.
The preoperative diagnosis and the clinical stage were 
based on contrast-enhanced computed tomography (CT) of 
the abdomen. All patients were examined with chest CT 
and a bone scan to confirm distant metastasis. Our fol-
low-up protocol consisted of a physical examination, 
chest-abdomen CT, and a complete metabolic profile every 
6 months.
ORN was performed through either a flank or a subcostal 
incision. Subcutaneous tissue and abdominal muscle were 
dissected and divided. After blunt dissection of the para-
renal space to mobilize the kidney, the peritoneum was in-
cised, and the posterior peritoneum and Gerota's fascia 
were divided. On approach to the hilar area, the renal ar-
tery was clamped. The renal vein and ureter were ligated 
and cut, and then the renal artery was ligated and cut. We 
extracted the kidney, which was surrounded by peri-
nephric fat and enveloped by Gerota’s fascia, while main-
taining the position of the Jackson-Pratt drain at the renal 
fossa. Para-aortic or paracaval and hilar lymph node dis-
section (LND) were performed when an enlarged lymph 
node was found radiologically before surgery or grossly 
during the operation.
LRN was performed by use of the transperitoneal ap-
proach in all cases. Pneumoperitoneum was achieved by 
using a Veress needle, and 3 or 4 ports were placed depend-
ing on the case. After laterocolic incision and mobilization 
of the colon, the renal hilum was dissected in the standard 
fashion with adequate visualization of the renal vein and 
artery. We used 3 or 4, 10 or 15 mm Hem-o-Lok clips 
(Teleflex Medical, Research Triangle Park, NC, USA) to 
control the renal artery. The renal vein was controlled by 
3 or 4, 15 mm clips. We removed the kidney, which was sur-
rounded by the perinephric fat and enveloped by Gerota’s 
fascia, with or without a concomitant adrenalectomy. All 
of the specimens were removed intact without morcellation 
or fragmentation in an Endo Catch retrieval bag (Covidien, 
Dublin, Ireland) through a lower abdominal incision. An 
indwelling Jackson-Pratt drain was placed in the retro-
peritoneal space through a 5 mm port site in all of the 
patients. Para-aortic or paracaval and hilar LND were per-
formed in the same way as ORN.     
The continuous variables were compared with an in-
dependent Student’s t-test. The categorical variables were 
assessed by using the chi-square test. The 5-year overall 
survival, the cancer-specific survival, and the recurrence- 
free survival were analyzed by using the Kaplan-Meier 
method. All p-values were 2-sided, and p＜0.05 was consid-
ered significant. Analyses were conducted by using the 
SPSS ver. 12.0 software (SPSS Inc., Chicago, IL, USA).
RESULTS
There were no significant differences in age, sex, BMI, or 
tumor laterality between the LRN and ORN groups. The 
pathologic data, including tumor size and grade, did not dif-
fer significantly between the groups (p=0.593 and p=0.857, 
respectively). The mean operative time was similar in the 
LRN and ORN groups (209.0 minutes vs. 205.1 minutes, 
p=0.755). There was a significant increase in ABL in the 
ORN group (287.6 ml vs. 431.5 ml, p=0.035). The complica-
tion rate did not differ statistically between the LRN and 
ORN groups (6.0% vs. 14.2%, p=0.265). There were no ma-Korean J Urol 2011;52:474-478
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TABLE 2. Comparison of long-term oncologic outcomes between 
LRN ORN p-value
Mean follow up (mo)
Distant metastases (%)
Lung
Bone
Liver
% 5-year survival
Overall
Cancer-specific
Recurrence-free
60.0±10.7
5
    5 (100.0)
0 (0.0)
0 (0.0)
87.8
93.9
84.8
65.6±7.0
6
3 (50.0)
1 (16.7)
2 (30.3)
85.7
88.5
85.7
0.597
0.513
0.910
0.842
LRN: laparoscopic radical nephrectomy, ORN: open radical nephrectomy
jor complications that required conversion to an open pro-
cedure or reoperation. According to the complication classi-
fication system suggested by Clavien et al [15], 2 (100%) 
complications in the LRN group were grade I; in the ORN 
group, 4 (80%) were grade I and 1 (20%) was grade II. Grade 
III or IV complications did not occur in our series. Two cases 
of chylous ascites occurred in the LRN group; 1 case of pneu-
mothorax and 2 cases of pneumonia and ileus occurred in 
the ORN group. All cases were managed by conservative 
treatment (Table 1).    
The mean follow-up was 60.0 months (range, 48.0-77.0 
months) in the LRN group. Cancer recurrence was noted 
in 5 patients between 24 and 57 months; in all cases, the 
lung was the site of recurrence. Two of 5 patients died at 
58 and 66 months after nephrectomy, respectively. The 
other 3 patients displayed recurrences at 24, 35, and 47 
months; they survived to 50, 55, and 56 months, respec-
tively. The 5-year overall survival, the cancer-specific sur-
FIG. 1. (A) Kaplan-Meier overall survival curve. (B) Kaplan- 
Meier cancer specific survival curve. (C) Kaplan-Meier 
recurrence-free survival curve.Korean J Urol 2011;52:474-478
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vival, and the recurrence-free survival rates were 87.8%, 
93.9%, and 84.8%, respectively (Table 2).  
The mean follow-up was 65.6 months (range, 56.0-77.0) 
in the ORN group. Cancer recurrence was noted in 6 pa-
tients between 21 and 42 months; the site of recurrence was 
the lung in 3 cases, the liver in 2 cases, and the bones in 
1 case. Four of 6 patients died between 57 and 60 months. 
The other 2 patients exhibited recurrence at 28 and 38 
months; they lived to 55 months after the operation. The 
5-year overall, cancer-specific, and recurrence-free surviv-
al rates were 85.7%, 88.5%, and 82.8%, respectively (Table 
2).
For the LRN and ORN groups, respectively, the 5-year 
overall survival rate, the cancer-specific survival rate, and 
the recurrence-free survival rate were not significantly 
different. The 5-year overall survival rates were 87.8% and 
85.7% (p=0.513), respectively; the cancer-specific survival 
rates were 93.9% and 88.5% (p=0.910), respectively; and 
the recurrence-free survival rates were 84.8% and 82.8% 
(p=0.842), respectively. Kaplan-Meier curves for the 
5-year overall survival rate, the cancer-specific survival 
rate, and the recurrence-free rate are presented in Fig. 1. 
DISCUSSION
Recently, the operative and the oncologic efficacy of laparo-
scopic applications have been established by numerous 
studies [2-9]. LRN has emerged as the standard of care in 
most patients with T1 RCC who are not candidates for 
nephron-sparing surgery [2,3]. However, most studies 
were confined to small-sized tumors; few recent pub-
lications have addressed the role of LRN for large renal 
tumors. Moreover, recent studies have suggested the use 
of nephron-sparing techniques for small-sized renal tu-
mors; these techniques include partial nephrectomy, ra-
dio-frequency ablation, and cryotherapy. Therefore, the in-
dications for LRN are expanding to encompass increas-
ingly larger tumors [13]. 
Dunn et al reviewed the Washington University 9-year 
experience with LRN; all tumors were ≥4 cm and ＜10 cm 
[10]. The operative time was longer in LRN than in ORN 
(321 minutes vs. 143 minutes, p＜0.001); however, the esti-
mated blood loss (EBL) was significantly less and hospital 
stay was significantly shorter. Steinberg et al compared 
the operative outcomes for LRN and ORN in T2 RCC [16]. 
LRN was associated with a shorter operative time (180 mi-
nutes vs. 207 minutes, p=0.03), reduced EBL, and a shorter 
hospital stay. Kim et al retrospectively evaluated the re-
sults of LRN and ORN groups with respect to T2 RCC [12]. 
LRN was associated with a shorter operative time (190.9 
minutes vs. 213.8 minutes, p=0.039), less EBL, and a short-
er hospital stay. Several institutions have reported various 
LRN operative times for T2 RCC; however, the blood loss 
and the length of the hospital stay were generally less in 
LRN than in ORN. In our study, LRN had an operative time 
(209.0 minutes vs. 205.1 minutes, p=0.755) and complica-
tion rate (6% vs. 14%, p=0.265) similar to ORN. However, 
the LRN group showed significantly less ABL (287.6 ml vs. 
431.5 ml, p=0.035) than did the ORN group. Our LRN oper-
ative times were somewhat longer than for ORN. We think 
that the many cases of LRN during the early period of the 
learning curve influenced the operative times for LRN in 
our study. More recently, the LRN operative time for T2 
RCC is about 150 minutes in our clinic, which seems to be 
short compared with the operative times for ORN. We be-
lieve that LRN for T2 RCC has more benefit than ORN in 
operative times. Shorter operative times may have a favor-
able effect on the patient’s postoperative period. 
The transperitoneal approach has the benefit of a wider 
working space and readily identifiable anatomical land-
marks. Moreover, it may be advantageous in patients with 
hilar lymphadenopathy and renal vein involvement [10, 
17,18]. Larger tumors occupy an increased proportion of 
the retroperitoneum, often protruding into the abdominal 
cavity, thus limiting the space available for laparoscopy. 
Larger tumors are also more vascular, and there is an in-
creased incidence of multiple feeding vessels in larger renal 
cancers. It is generally accepted that the necessity of LND 
is greater for larger renal tumors than for small renal 
tumors. Therefore, LRN is a technical challenge, even 
when performed by experienced laparoscopic surgeons. We 
performed all laparoscopic surgeries by using the trans-
peritoneal approach to create a larger working space, to 
identify the perinephric space, and to perform LND in case 
it was necessary. 
Long-term oncologic outcomes after ORN for T2 RCC are 
well documented, but LRN cases remain rare. Portis et al 
analyzed 64 patients undergoing LRN and 69 patients un-
dergoing ORN before 1996 (median follow-up, 54 months) 
and reported that the 5-year overall, cancer-specific, and 
recurrence-free survival rates in the LRN groups for pa-
tients with RCC ≥7 cm were 89%, 100%, and 87%, com-
pared with 86%, 83%, and 87%, respectively, in the ORN 
groups [19]. Hemal et al reported on 112 patients with 
pathological T2 RCC treated with LRN and ORN [20]. The 
5-year overall, cancer-specific, and recurrence-free surviv-
al rates for LRN were 87.8%, 95.1%, and 92.6%, compared 
with 88.7%, 94.4%, and 90.1%, respectively, for ORN. 
Berger et al presented long-term oncologic outcomes of 73 
LRN patients [21]. The 5-year overall, cancer-specific, and 
recurrence-free survival rates for LRN in T2 RCC were 
81.0%, 90.0%, and 92.0%. In these retrospective reviews, 
the authors demonstrated that long-term survival after 
LRN was equivalent to that after ORN. Our primary aim 
was to report the long-term oncologic outcome of LRN for 
the management of T2 RCC. Therefore, we compared our 
results with other laparoscopic series. In the LRN groups, 
our 5-year overall, cancer-specific, and recurrence-free 
survival rates were 87.8%, 93.9%, and 84.8%, respectively. 
These results seem to be similar to the long-term oncologic 
outcomes reported in other laparoscopic series. In addition, 
in the ORN groups, our 5-year overall, cancer-specific, and 
recurrence-free survival rates were 85.7%, 88.5%, and 
82.8%, respectively. These results are also consistent with Korean J Urol 2011;52:474-478
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the LRN groups. As a result, we conclude that LRN is effica-
cious as a therapeutic modality for large renal cancer and 
will have an impact on oncologic outcome.  
The limitations of our study were that it was retro-
spective and nonrandomized. However, it is very difficult 
to perform a prospective randomized study for LRN vs ORN 
outcomes in T2 RCC. Our study is significant in that the 
mean follow-up time was long enough to evaluate the 
long-term oncologic outcomes of LRN and ORN, and the 
surgical techniques were standardized. Moreover, this is 
the first report of the long-term oncologic outcomes of LRN 
for T2 RCC in Korea. 
CONCLUSIONS
Large renal tumors (≥7 cm) can be safely resected lapa-
roscopically with less blood loss than is involved in open 
radical nephrectomy, with comparable surgical outcomes. 
During long-term follow-up, LRN achieved a degree of can-
cer control similar to that obtained with ORN. A larger, 
population-based study appears to be necessary for further 
validation of these findings.
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